anbal-cel: updated results from phase i study of novel cd19-targeting car-t therapy
Published 1 year ago • 77 plays • Length 2:19Download video MP4
Download video MP3
Similar videos
-
1:12
anbal-cel: a novel anti-cd19 car-t therapy with dual silencing of pd-1 & tigit for lbcl
-
4:24
investigating production failure and out-of-specification production of car t-cell therapeutics
-
2:20
design of a phase i trial of allogeneic anti-cd123 car t-cells in r/r aml
-
2:05
results from the phase i sal-relax trial: venetoclax plus cytarabine and mitoxantrone in r/r aml
-
6:20
updated pivotal eliana study results for car t-cell product tisagenlecleucel in all
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
2:00
update of a phase i trial investigating lintuzumab-ac225 plus venetoclax in r/r aml
-
2:13
interim analysis of phase ii study of zamto-cel in r/r dlbcl
-
11:47
what's the latest on car-t in all?
-
1:04
horizon scan of novel and upcoming aml therapies
-
2:49
results of a phase i trial investigating cynk-001, a placental nk-cell product, in patients with aml
-
1:58
car t-cell therapy and all: the current landscape
-
8:27
anti cd7 car t-cell therapy in t-all
-
2:53
autohct in dlbcl in the car-t era
-
17:23
updates in cll: key clinical trials in the frontline and r/r setting, pre-clinical data and mrd
-
2:45
the value of axi-cel as a second-line treatment in r/r lbcl
-
2:37
allo-hsct for cll in the era of novel agents
-
1:32
an update from bellwave-001: nemtabrutinib in cll/sll
-
0:33
itoc 2022 highlights: b-cell engineering for cancer treatment